We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n53), RAEB in transformation (RAEB-T, n29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n57) or alternative family donor (n1). Stem cell source was bone marrow (n69) or peripheral blood (n28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS.

, ,
doi.org/10.1038/leu.2010.297, hdl.handle.net/1765/33972
Erasmus MC: University Medical Center Rotterdam

Strahm, B., Nöllke, P., Zecca, M., Korthof, E., Bierings, M., Furlan, I., … Locatelli, F. (2011). Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: Results of the EWOG-MDS 98 study. Leukemia, 25(3), 455–462. doi:10.1038/leu.2010.297